| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 06/19/2002 | EP1215214A1 Novel polypeptide |
| 06/19/2002 | EP1215212A2 Dihydro derivatives of LL-E33288 antibiotics |
| 06/19/2002 | EP1215203A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 06/19/2002 | EP1214948A2 Antibacterial composition for controlling airborne bacteria and corresponding procedure |
| 06/19/2002 | EP1214945A2 Method and medicament for inhibiting the expression of a defined gene |
| 06/19/2002 | EP1214943A1 T-cell therapeutics for transmissible spongiform encephalopathy and method for the manufacture of non-infective blood products and tissue derived products |
| 06/19/2002 | EP1214933A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected |
| 06/19/2002 | EP1214443A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 06/19/2002 | EP1214422A1 Phosphatases which activate map kinase pathways |
| 06/19/2002 | EP1214417A2 Nucleic acids and proteins from group b streptococcus |
| 06/19/2002 | EP1214416A2 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
| 06/19/2002 | EP1214409A1 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| 06/19/2002 | EP1214404A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 06/19/2002 | EP1214396A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic |
| 06/19/2002 | EP1214344A1 Dipeptidyl peptidases |
| 06/19/2002 | EP1214342A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies |
| 06/19/2002 | EP1214335A1 Gamma-carboxyglutamate containing conopeptides |
| 06/19/2002 | EP1214332A1 Charge-modified nucleic acid terminators |
| 06/19/2002 | EP1214326A1 Inhibitors of prenyl-protein transferase |
| 06/19/2002 | EP1214325A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 06/19/2002 | EP1214324A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 06/19/2002 | EP1214320A1 Pyrido-pyridazine derivatives as ligands for gaba receptors |
| 06/19/2002 | EP1214317A1 Antiviral agents |
| 06/19/2002 | EP1214314A2 Aminopiperidine derivatives as antibacterials |
| 06/19/2002 | EP1214300A2 Rate-controlled particles |
| 06/19/2002 | EP1214295A2 Hydroxyacetamidobenzenesulphonamide derivatives |
| 06/19/2002 | EP1214293A1 Non-peptidic cyclophilin binding compounds and their use |
| 06/19/2002 | EP1214095A1 Use of anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 06/19/2002 | EP1214094A1 Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 06/19/2002 | EP1214089A1 Therapeutic uses of m3 polypeptide |
| 06/19/2002 | EP1214088A1 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines |
| 06/19/2002 | EP1214082A2 Methods and compositions for reducing immune response |
| 06/19/2002 | EP1214074A2 Dioxolane nucleoside analogs for the treatment or prevention of viral infection |
| 06/19/2002 | EP1214064A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 06/19/2002 | EP1214054A1 Intranasal influenza virus vaccine |
| 06/19/2002 | EP1214053A1 Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one nonionic surfactant |
| 06/19/2002 | EP1214052A1 Veterinary formulation for administration of a water-insoluble drug to a target animal through a water distribution system |
| 06/19/2002 | EP1214041A2 Combination therapy for the treatment of sepsis |
| 06/19/2002 | EP1105395B1 Photocyclized rapamycins |
| 06/19/2002 | EP0937092B1 Solid support matrices containing a toxin binding oligosaccharide |
| 06/19/2002 | EP0869817B1 Covalent lipid-phosphono-carboxylic acid conjugates and application thereof as antiviral medicaments |
| 06/19/2002 | EP0852497B1 Use of prostane derivatives and the combination thereof with antibiotics in the treatment of bacterial infections |
| 06/19/2002 | EP0754061B1 New oral pharmaceutical dosage form |
| 06/19/2002 | EP0625204B1 Hepatitis therapeutics |
| 06/19/2002 | EP0611397B1 Feline leukemia virus vaccines |
| 06/19/2002 | EP0574487B1 Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b |
| 06/19/2002 | EP0462215B1 MOLECULAR CLONING OF GENOMIC AND cDNA SEQUENCES ENCODING CELLULAR RECEPTORS FOR POLIOVIRUS |
| 06/19/2002 | CN1354800A Recombinant newcastle disease virus RNA expression systems and vaccines |
| 06/19/2002 | CN1354798A Process for preparation of pseudomonic acid A antibiotic by microbiological method |
| 06/19/2002 | CN1354746A 6.7-disubstituted-5,8-quinolinedione derivatives as antifungal agent |
| 06/19/2002 | CN1354675A Adjuvant combination formulations |
| 06/19/2002 | CN1354674A Synthetic peptide vaccines for foot-and-mouth disease |
| 06/19/2002 | CN1354672A Composition comprising alkaline sphingomyelinase for use as dietetic preparation, food supplement or pharmaceutical product |
| 06/19/2002 | CN1354663A Sulfonamide and sulfamide substituted imidazoquinolines |
| 06/19/2002 | CN1354658A New use of compounds as antibacterial agents |
| 06/19/2002 | CN1354656A Compositions and methods for mucosal delivery |
| 06/19/2002 | CN1354640A Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 06/19/2002 | CN1354016A 双价活疫苗胶囊剂 Bivalent vaccine capsules |
| 06/19/2002 | CN1354010A Shuangjinlian oral liquid for curing cold and influenza, and its preparing method |
| 06/19/2002 | CN1354005A Medicine for curing tinea manuum and tinea pedis and preparing method thereof |
| 06/19/2002 | CN1353993A Compounded medicine for curing dermatophytid infection |
| 06/19/2002 | CN1353986A Antibiotic agent of antihelicobacter pylori containing chelate compound |
| 06/19/2002 | CN1353980A Quick-acting aerosol for relieving asthma and its preparation method |
| 06/19/2002 | CN1086421C Synthesis and clone of composite polyvalent vaccine gene for type-C hepatitis virus |
| 06/19/2002 | CN1086290C Composition for treating condyloma acuminata |
| 06/18/2002 | US6407288 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents |
| 06/18/2002 | US6407257 Derivatives of erythromycin, their preparation process and their use as medicaments |
| 06/18/2002 | US6407246 Reverse transcriptase inhibitors to treat hiv |
| 06/18/2002 | US6407244 Antiproliferative agent |
| 06/18/2002 | US6407133 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 06/18/2002 | US6407131 5-carbonyloxy-1h-benzimidazole-2-carbamate derivatives |
| 06/18/2002 | US6407129 Azole compounds, their production and their use |
| 06/18/2002 | US6407091 β-lactamase inhibiting compounds |
| 06/18/2002 | US6407078 AZT derivatives exhibiting spermicidal and anti-viral activity |
| 06/18/2002 | US6407077 Administering b-l-(-2*-azido)-2*,3*-dideoxy-5-fluorocytidine derivative; acquired immune deficiency syndromoe (aids) treatment |
| 06/18/2002 | US6406885 Plant cell transformation vectors and dna code intimin |
| 06/18/2002 | US6406865 Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies |
| 06/18/2002 | US6406702 Multivalent in ovo avian vaccine |
| 06/18/2002 | US6406701 Reducing the susceptibility of t lymphocytes to hiv infection |
| 06/18/2002 | US6406698 Pharmaceutical composition comprising serum amyloid P component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components |
| 06/18/2002 | US6406694 Anti-CCR2 antibodies |
| 06/18/2002 | US6406688 Method of treating sepsis and ARDS with chemokine β-4 |
| 06/18/2002 | US6406681 Propellents and drugs |
| 06/18/2002 | CA2356812A1 Tnf-alpha production inhibitor comprising kavalactone as an active ingredient |
| 06/13/2002 | WO2002046749A2 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | WO2002046461A2 Method for identifying modulators of transcription |
| 06/13/2002 | WO2002046459A2 Method for the determination of at least one functional polymorphism in the nucleotide sequence of a preselected candidate gene and its applications |
| 06/13/2002 | WO2002046423A2 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines |
| 06/13/2002 | WO2002046409A2 Proteins and nucleic acids encoding same |
| 06/13/2002 | WO2002046384A2 Kinases and phosphatases sequences, and use thereof |
| 06/13/2002 | WO2002046383A2 Protein modification and maintenance molecules |
| 06/13/2002 | WO2002046233A1 Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof |
| 06/13/2002 | WO2002046230A2 G-protein coupled receptors |
| 06/13/2002 | WO2002046208A2 Method of producing biospecific molecules by protein trans-splicing |
| 06/13/2002 | WO2002046204A1 6-0-carbamoyl ketolide derivatives of erythromycin useful as antibacterials |
| 06/13/2002 | WO2002046197A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | WO2002046194A2 Substituted imidazopyridines |
| 06/13/2002 | WO2002046193A2 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | WO2002046192A2 Thioether substituted imidazoquinolines |
| 06/13/2002 | WO2002046191A2 Urea substituted imidazoquinoline ethers |